Relutrigine for spasms, infantile

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Jun 2025: Trial registered, NCT07010471
  2. 9 Jul 2025: Trial started, NCT07010471

The trials

NCT07010471: A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

State
Under way
Phase
Phase 3
People
160 planned
Started
9 Jul 2025
Primary completion
Dec 2026
Arms
Part A: Double-Blind Treatment Period, Part B: Open-Label Extension Treatment Period
Results
None posted
  1. 8 Jun 2025: Trial registered
  2. 9 Jul 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.